Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1983 Sep;80(1):141–148. doi: 10.1111/j.1476-5381.1983.tb11059.x

Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl.

V Glover, C J Pycock, M Sandler
PMCID: PMC2044979  PMID: 6418254

Abstract

Clorgyline (1 and 10 microM) and (+)-deprenyl (10 microM) both significantly potentiated the tyramine (100 microM)-induced release of [3H]-noradrenaline from rat cerebral cortex slices. (-)-Deprenyl (50 microM) significantly reduced it, while lower concentrations had no effect on noradrenaline release. However, in combination, 1 microM (-)-deprenyl blocked the release-facilitating action of 1 microM clorgyline, and 10 microM (-)-deprenyl that of 10 microM (+)-deprenyl. Low concentrations of (+)- and (-)-deprenyl (1 and 10 microM), both selectively inhibited phenylethylamine oxidation by monoamine oxidase B. Higher concentrations of (-)-deprenyl (20 and 50 microM) also inhibited 5-hydroxytryptamine oxidation by monoamine oxidase A. Clorgyline (1 and 10 microM) inhibited both enzymes. Thus, the effects of these drugs on noradrenaline-release cannot be explained solely in terms of irreversible inhibition of monoamine oxidase A and B, and other possible mechanisms are discussed. If the brain-slice model faithfully mirrors the sequence of events manifesting peripherally as the tyramine hypertensive response ('cheese effect'), then it is possible that low doses of (-)-deprenyl, administered with antidepressant monoamine oxidase inhibitors, can prevent this adverse reaction.

Full text

PDF
141

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLACKWELL B., MABBITT L. A. TYRAMINE IN CHEESE RELATED TO HYPERTENSIVE CRISES AFTER MONOAMINE-OXIDASE INHIBITION. Lancet. 1965 May 1;1(7392):938–940. doi: 10.1016/s0140-6736(65)91257-2. [DOI] [PubMed] [Google Scholar]
  2. Elsworth J. D., Glover V., Reynolds G. P., Sandler M., Lees A. J., Phuapradit P., Shaw K. M., Stern G. M., Kumar P. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology (Berl) 1978 Apr 14;57(1):33–38. doi: 10.1007/BF00426954. [DOI] [PubMed] [Google Scholar]
  3. Finberg J. P., Tenne M., Youdim M. B. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol. 1981 May;73(1):65–74. doi: 10.1111/j.1476-5381.1981.tb16772.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Garcha G., Imrie P. R., Marley E., Thomas D. V. Distribution and effects of intestinally administered [14C]-tyramine in cats, modified by monoamine oxidase inhibitors. J Psychiatr Res. 1982;17(1):75–92. doi: 10.1016/0022-3956(82)90035-8. [DOI] [PubMed] [Google Scholar]
  5. Green A. L., El Hait M. A. A new approach to the assessment of the potency of reversible monoamine oxidase inhibitors in vivo, and its application to (+)-amphetamine, p-methoxyamphetamine and harmaline. Biochem Pharmacol. 1980 Oct 15;29(20):2781–2789. doi: 10.1016/0006-2952(80)90012-x. [DOI] [PubMed] [Google Scholar]
  6. Kerwin R. W., Pycock C. J. The effect of some putative neurotransmitters on the release of 5-hydroxytryptamine and gamma-aminobutyric acid from slices of the rat midbrain raphe area. Neuroscience. 1979;4(9):1359–1365. doi: 10.1016/0306-4522(79)90163-5. [DOI] [PubMed] [Google Scholar]
  7. Knoll J., Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972;5:393–408. [PubMed] [Google Scholar]
  8. Knoll J. The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J Neural Transm. 1978;43(3-4):177–198. doi: 10.1007/BF01246955. [DOI] [PubMed] [Google Scholar]
  9. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  10. Lader M. H., Sakalis G., Tansella M. Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia. 1970 Aug 19;18(1):118–123. doi: 10.1007/BF00402391. [DOI] [PubMed] [Google Scholar]
  11. Lewinsohn R., Glover V., Sandler M. Development of benzylamine oxidase and monoamine oxidase A and B in man. Biochem Pharmacol. 1980 May 1;29(9):1221–1230. doi: 10.1016/0006-2952(80)90278-6. [DOI] [PubMed] [Google Scholar]
  12. Lipper S., Murphy D. L., Slater S., Buchsbaum M. S. Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology (Berl) 1979 Apr 11;62(2):123–128. doi: 10.1007/BF00427124. [DOI] [PubMed] [Google Scholar]
  13. Mann J. J., Frances A., Kaplan R. D., Kocsis J., Peselow E. D., Gershon S. The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. J Clin Psychopharmacol. 1982 Feb;2(1):54–57. doi: 10.1097/00004714-198202000-00008. [DOI] [PubMed] [Google Scholar]
  14. Mendis N., Pare C. M., Sandler M., Glover V., Stern G. M. Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology (Berl) 1981;73(1):87–90. doi: 10.1007/BF00431109. [DOI] [PubMed] [Google Scholar]
  15. Miller H. H., Shore P. A., Clarke D. E. In vivo monoamine oxidase inhibition by d-amphetamine. Biochem Pharmacol. 1980 May 15;29(10):1347–1354. doi: 10.1016/0006-2952(80)90429-3. [DOI] [PubMed] [Google Scholar]
  16. Paykel E. S., Rowan P. R., Parker R. R., Bhat A. V. Response to phenelzine and amitriptyline in subtypes of outpatient depression. Arch Gen Psychiatry. 1982 Sep;39(9):1041–1049. doi: 10.1001/archpsyc.1982.04290090035008. [DOI] [PubMed] [Google Scholar]
  17. Pickar D., Cohen R. M., Jimerson D. C., Lake C. R., Murphy D. L. Tyramine infusions and selective monoamine oxidase inhibitor treatment. II. Interrelationships among pressor sensitivity changes, platelet MAO inhibition, and plasma MHPG reduction. Psychopharmacology (Berl) 1981;74(1):8–12. doi: 10.1007/BF00431748. [DOI] [PubMed] [Google Scholar]
  18. Pickar D., Cohen R. M., Jimerson D. C., Murphy D. L. Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity. Psychopharmacology (Berl) 1981;74(1):4–7. doi: 10.1007/BF00431747. [DOI] [PubMed] [Google Scholar]
  19. Reynolds G. P., Elsworth J. D., Blau K., Sandler M., Lees A. J., Stern G. M. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol. 1978 Dec;6(6):542–544. doi: 10.1111/j.1365-2125.1978.tb00883.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sandler M., Glover V., Ashford A., Esmail A. The inhibition of tyramine oxidation and the tyramine hypertensive response ("cheese effect") may be independent phenomena. J Neural Transm. 1980;48(4):241–247. doi: 10.1007/BF01250659. [DOI] [PubMed] [Google Scholar]
  21. Sandler M. Monoamine oxidase inhibitor efficacy in depression and the "cheese effect". Psychol Med. 1981 Aug;11(3):455–458. doi: 10.1017/s0033291700052764. [DOI] [PubMed] [Google Scholar]
  22. Simpson L. L. Evidence that deprenyl, A type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine. Biochem Pharmacol. 1978;27(11):1591–1595. doi: 10.1016/0006-2952(78)90490-2. [DOI] [PubMed] [Google Scholar]
  23. Squires R. F. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol. 1972;5:355–370. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES